Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
April 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | |
| 7 | 8 | 9 | 10 | 11 | 12 | 13 |
| 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| 21 | 22 | 23 | 24 | 25 | 26 | 27 |
| 28 | 29 | 30 |
May 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | |||
| 5 | 6 | 7 | 8 | 9 | 10 | 11 |
| 12 | 13 | 14 | 15 | 16 | 17 | 18 |
| 19 | 20 | 21 | 22 | 23 | 24 | 25 |
| 26 | 27 | 28 | 29 | 30 | 31 |
June 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | ||||||
| 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| 16 | 17 | 18 | 19 | 20 | 21 | 22 |
| 23 | 24 | 25 | 26 | 27 | 28 | 29 |
| 30 |
Press releases published on March 31, 2025
Medify Air Donates Over 1,000 Air Purifiers to the Collier Disaster Alliance
EIN Presswire
·
March 31, 2025
Medify Air announced Monday that it recently donated over 1,000 air purifiers to the Collier Disaster Alliance center. BOCA RATON, FL, UNITED STATES, March 31, 2025 /EINPresswire.com/ -- Medify Air announced Monday that it recently donated over 1,000 …
Aspen Medical Products and Lovell Unite to Enhance Access to Pain Therapy for Veterans and Military Healthcare Systems
EIN Presswire
·
March 31, 2025
Aspen Medical Products and Lovell Collaborate to Provide Enhanced Pain Therapy Solutions for Veterans and Military Healthcare Systems PENSACOLA, FL, UNITED STATES, March 31, 2025 /EINPresswire.com/ -- Lovell® Government Services and Aspen Medical …
JARC FL CELEBRATES 39TH ANNUAL GALA, RAISING OVER $1.1 MILLION FOR PROGRAMS SUPPORTING INDIVIDUALS WITH DISABILITIES
EIN Presswire
·
March 31, 2025
Event Honored Champions for Special Needs While Raising Money for Adults with Intellectual and Developmental Disabilities BOCA RATON, FL, UNITED STATES, March 31, 2025 /EINPresswire.com/ -- JARC Florida, a non-profit, non-sectarian organization that …
Scientific Industries Reports Financial Results for Fiscal Year Ended December 31, 2024 and Launches DOTS MPS for Cell Culture Biopharma Market
GlobeNewswire
·
March 31, 2025
BIOPROCESSING OPERATIONS: 24% REVENUE GROWTH DRIVEN BY NEWLY LAUNCHED PRODUCTS OPERATIONAL EFFICIENCIES CUT TOTAL NET LOSSES BY 29% LAUNCHED NEW STATE OF THE ART VIVID WORKSTATION Investor Call to be held Tuesday, April 1st at 11:00 a.m. Eastern Time …
Total number of shares and voting rights in Zealand Pharma as of March 31, 2025
GlobeNewswire
·
March 31, 2025
Company announcement – No. 8 / 2025 Total number of shares and voting rights in Zealand Pharma as of March 31, 2025 Copenhagen, Denmark, March 31, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a …
Glucotrack Reports Full Year 2024 Financial Results and Recent Corporate Highlights
GlobeNewswire
·
March 31, 2025
Transformational 2024: successfully advanced from preclinical to clinical stage company Strengthened leadership team to drive growth and advance clinical development Investigational Device Exemption (IDE) approval for continuous blood glucose monitoring ( …
Bavarian Nordic modtager FDA-godkendelse af frysetørret koppe- og mpoxvaccine
GlobeNewswire
·
March 31, 2025
KØBENHAVN, Danmark, 31. marts 2025 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at de amerikanske lægemiddelmyndigheder, U.S. Food and Drug Administration (FDA) har godkendt den frysetørrede version af vaccinen JYNNEOS® til forebyggelse af kopper og …
Bavarian Nordic Receives U.S. FDA Approval of Freeze-Dried Smallpox and Mpox Vaccine
GlobeNewswire
·
March 31, 2025
COPENHAGEN, Denmark, March 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced that the U.S. Food and Drug Administration (FDA) has approved the freeze-dried formulation of JYNNEOS® (Smallpox and Mpox Vaccine, Live, Non-replicating) for prevention …
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
GlobeNewswire
·
March 31, 2025
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced …
ANI Pharmaceuticals to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference
GlobeNewswire
·
March 31, 2025
PRINCETON, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, will host a fireside chat at the 2025 RBC Capital Markets …
Calidi Biotherapeutics Announces Closing of $3.9 Million Registered Direct Offering and Concurrent Private Placement
GlobeNewswire
·
March 31, 2025
SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the closing of its …
VAXIL’s Annual and Special Shareholders Meeting
GlobeNewswire
·
March 31, 2025
Not for distribution by US newswire or in United States NESS-ZIONA, Israel, March 31, 2025 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), announces that at the Company's Annual and Special General Meeting, held virtually, …
FibroBiologics Reports Full Year 2024 Financial Results and Provides Corporate Update
GlobeNewswire
·
March 31, 2025
Proprietary master cell bank of fibroblast-based spheroids product candidate, CYWC628, completed in accordance with Good Manufacturing Practices after successfully passing all required safety testing Preparations for Phase 1/2 clinical trial in Australia …
Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update
GlobeNewswire
·
March 31, 2025
NEW HOPE, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing …
Vivos Therapeutics Reports Full Year 2024 Financial Results and Provides Operational Update
GlobeNewswire
·
March 31, 2025
Year over year product revenue increased 26% Operating expenses declined 21% and year over year operating loss decreased 35% Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., March 31, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc …
Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
GlobeNewswire
·
March 31, 2025
BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- - Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of …
Zevra Therapeutics Files Preliminary Proxy
GlobeNewswire
·
March 31, 2025
Confirms Receipt of Two Director Nominees from Daniel J. Mangless Stockholders Are Not Required to Take Action at This Time CELEBRATION, Fla., March 31, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (Nasdaq:GS ZVRA) (“Zevra,” or the “Company”), a …
Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational Highlights
GlobeNewswire
·
March 31, 2025
Announced demonstrated ability to deliver transient gene therapy (payload) to tumors using systemic antitumor virotherapy platform Filed IND in March 2025 for CLD-201 company sponsored Phase 1 trial to treat multiple solid tumors Commencement of …
Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights
GlobeNewswire
·
March 31, 2025
Lead candidate ARD-101 demonstrated clinical activity and was generally well tolerated in a two-part Phase 2 trial in Prader-Willi Syndrome (PWS), with meaningful reductions in hyperphagia (up to a 16-point HQ-CT reduction, with an average reduction of …
Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights
GlobeNewswire
·
March 31, 2025
Mick Hitchcock, Ph.D., appointed Interim Chief Executive Officer Biomea preparing icovamenib for late-stage clinical development Multiple milestones anticipated in 2025 including: FDA meeting anticipated in first half 2025 to discuss icovamenib late-stage …